CHAPTER 1. INTRODUCTION
1.1. Market Definition
1.2. Executive Summary
1.3. The Scope of the Study
CHAPTER 2. RESEARCH METHODOLOGY
2.1. Secondary Research
2.2. Primary Research
2.3. Analytic Tools and Model
2.4. Economic Indicator
2.4.1 Base Year, Base Currency, Forecasting Period
2.5. Expert Validation
2.6. Study Timeline
CHAPTER 3. MARKET ANALYSIS
3.1. Industry Value Chain Analysis
3.2. Porter's Five Force Analysis
3.2.1. Bargaining Power of Buyers
3.2.2. Bargaining Power of Suppliers
3.2.3. Threats of Substitutes
3.2.4. Threats of New Entrants
3.2.5. Degree of Competition
3.3. PESTLE Analysis
3.3.1. Political
3.3.2. Economical
3.3.3. Social
3.3.4. Technological
3.3.5. Legal
3.3.6. Environmental
3.4. SWOT Analysis
3.4.1. Strengths
3.4.2. Weakness
3.4.3. Opportunities
3.4.4. Threats
3.5. Y-O-Y Analysis
CHAPTER 4. MARKET DYNAMICS
4.1. Market Drivers
4.1.1. Increase in the number of androgenic alopecia patients worldwide
4.1.2. Growing use of platelet-rich plasma in various therapeutic areas
4.1.3. Prevalence of arthritis
4.1.4. Increase in the number of androgenic alopecia patients worldwide
4.2. Market Restraints & Challenges
4.2.1. Lack of reimbursement policies
4.2.2. Varying prices of plasma therapy
4.2.3. Developments in other fields of regenerative medicine
4.3. Market Opportunities
4.3.1. Increase in the number of patients suffering from orthopaedic disorders and
androgenic alopecia
CHAPTER 5. GLOBAL PLASMA THERAPY MARKET – BY TYPE
5.1. Pure PRP
5.2. Leukocyte-Rich PRP
5.3. Pure Platelet-Rich Fibrin
5.4. Leukocyte-Rich Fibrin
CHAPTER 6. GLOBAL PLASMA THERAPY MARKET – BY SOURCE TYPE
6.1. Autologous
6.2. Allogenic
CHAPTER 7. GLOBAL PLASMA THERAPY MARKET – BY APPLICATION
7.1. Orthopaedic
7.1.1. Arthritis
7.1.2. Chronic Tendinitis
7.1.3. Bone Repair & Regeneration
7.2. Dermatology
7.2.1. Androgenic Alopecia
7.2.2. Plastic Surgery
7.3. Cardiac Muscle Injury
7.4. Dental
7.5. Nerve Injury
7.6. Others
CHAPTER 8. GLOBAL PLASMA THERAPY MARKET – BY END USER
8.1. Hospitals & Clinics
8.2. Research Institutes
CHAPTER 9. GLOBAL PLASMA THERAPY MARKET - BY GEOGRAPHY
9.1. Introduction
9.2. North America
9.2.1. U.S.
9.2.2. Canada
9.2.3. Mexico
9.2.4. Costa Rica
9.3. South America
9.3.1. Brazil
9.3.2. Argentina
9.3.3. Chile
9.3.4. Columbia
9.3.5. Others
9.4. Europe
9.4.1. U.K.
9.4.2. Germany
9.4.3. France
9.4.4. Italy
9.4.5. Spain
9.4.6. Russia
9.4.7. Netherlands
9.4.8. Switzerland
9.4.9. Poland
9.4.10. Others
9.5. APAC
9.5.1. China
9.5.2. Japan
9.5.3. India
9.5.4. South Korea
9.5.5. Australia & New Zealand
9.5.6. Malaysia
9.5.7. Singapore
9.5.8. Others
9.6. Middle East & Africa
9.6.1. UAE
9.6.2. Saudi Arabia
9.6.3. Iran
9.6.4. Iraq
9.6.5. Qatar
9.6.6. South Africa
9.6.7. Algeria
9.6.8. Morocco
9.6.9. Nigeria
9.6.10. Egypt
9.6.11. Others
CHAPTER 10. GLOBAL PLASMA THERAPY MARKET - COMPANY PROFILES
10.1. CSL Ltd.
10.2. Grifols International S.A.
10.3. Kedrion S.P.A.
10.4. LFB SA
10.5. Bio Product Laboratory Ltd. (BPL)
10.6. China Biologic Products, Inc.
10.7. Octapharma AG
10.8. Biolife Plasma Services
10.9. Cambryn Biologics LLC
10.10. Biotest
10.11. Cambryn Biologics LLC
10.12. Pluristem Therapeutics
10.13. Cellular Biomedicine Group
10.14. Caladrius Biosciences
CHAPTER 11. GLOBAL PLASMA THERAPY MARKET - COMPETITIVE
LANDSCAPE
11.1. Market Share Analysis
11.2. Strategies adopted by top companies
11.3. Mergers, Acquisitions, Collaborations & Agreements
CHAPTER 12. MARKET INSIGHTS
12.1. Industry Experts Insights
12.2. Analysts Opinions
12.3. Investment Opportunities
CHAPTER 13. APPENDIX
13.1. List of Tables
13.2. List of Figures